Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Bellmunt, J ^a,b   Albiol, S ^b   Kataja, V ^c,d  

^a HOSPITAL DEL MAR   (Spain)

^b Instituto Oncologico Teknon   (Spain)

^c VAASA CENTRAL HOSPITAL   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CARBOPLATIN; CISPLATIN; CREATININE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; TAXANE DERIVATIVE; VINBLASTINE; VINFLUNINE;

ANTIANGIOGENIC THERAPY; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER PRESSURE; BLOOD CELL COUNT; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CYSTECTOMY; HISTORY OF MEDICINE; HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; THORAX RADIOGRAPHY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINE CYTOLOGY;

EUROPE; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASM INVASIVENESS; SOCIETIES, MEDICAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 66549119867     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp136     Document Type: Article

References (23)

1. Epstein JI, Amen MD, Reuter UR et al. The World Health Organization International Society of Urologic Pathology (ISUP) consensus classification of urothelial (transitional cell) lesions, neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-1448.
2. Smith JA, Labasky RF, Cockett K et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). J Urol 1999; 162: 1697-1701.
3. Sylvester R, Oosterlinck W, van der Meijden A. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A metaanalysis of published results of randomized clinical trials. J Urol 2004; 171: 2186-2190.
4. Skinner DG, Stein JP, Lieskovsky G et al. Twenty-five-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 1998; 33 (Suppl): 25-26.
5. Stien JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients. J Clin Oncol 2001; 19: 666-675.
6. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19: 89-93.
7. Rodel C, Grabenbauer GG, Kuhn R et al. Combined modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002; 20: 3061-3071.
8. Shipley WU, Kaufman DS, Zehr EM et al. Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60: 62-67.
9. Hussain SA, Stocken DD, Peake DR et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 2004; 90: 2106-2111.
10. Sternberg CN. Neo-adjuvant and adjuvant chemotherapy of bladder cancer. Is there a role? Ann Oncol 2002; 13 (Suppl 4): 273-279.
11. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866.
12. Sherif A, Holmberg L, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies. Eur Urol 2004; 45: 297-303.
13. Winquist E, Kirchner TS, Segal R et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. J Urol 2004; 171: 561-569.
14. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant cisplatin for advanced bladder cancer. Cochrane Database Syst Rev 2006; issue 2.
15. Advanced Bladder Cancer Overview Collaboration. Adjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2006; issue 2.
16. Sternberg CN, Calabro F. Adjuvant chemotherapy for bladder cancer. Expert Rev Anticancer Ther 2005; 5: 987-992.
17. Bellmunt J, de Wit R, Albiol S. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol 2003; 47: 195-206.
18. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, cisplatin vinblastine, doxorubicin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, phase III study. J Clin Oncol 2000; 17: 3068-3077.
19. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608.
20. Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69 (1 Suppl): 62-79.
21. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/ cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy. EORTC30987/Intergroup Study. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings part I, vol. 25, no. 18S.
22. Bellmunt J, Maroto P, Mellado B et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. Proc 2008 ASCO Genitourinary Cancers Symposium (Abstr 291).
23. Bellmunt J, von der Maase H, Theodore C et al. Randomized phase III trial of vinflunine (VFL) plus best supportive care (BSC) versus BSC alone as 2nd line therapy after a platinum-containing regimen, in advanced transitional cell carcinoma of the urothelium (TCCU). J Clin Oncol. 2008 ASCO Annual Meeting Proceedings part I, vol. 26.